Marcello Di Nisio
University of Amsterdam
Publications 152
Abstract Background The safety and efficacy of edoxaban and dalteparin is unclear for several cancer groups. Methods We evaluated the occurrence of the primary outcome in large cancer groups. The primary outcome was the composite of recurrent VTE or major bleeding over 12 months. Results In patients with gastrointestinal cancer, the primary outcome occurred in 19.4% patients given edoxaban and in 15.0% given dalteparin (risk difference [RD], 4.4%; 95%-CI, −4.1% to 12.8%). The corresponding rates...
Introduction In cancer patients, current guidance suggests similar treatment for incidental and symptomatic venous thromboembolism (VTE), mainly based on retrospective data. We aimed to evaluate anticoagulant therapy in cancer patients with incidental and symptomatic VTE. Methods The Hokusai VTE Cancer study was a randomised controlled trial comparing edoxaban with dalteparin for cancer-associated VTE. The primary outcome was the composite of first recurrent VTE or major bleeding. Secondary outc...
#1Paolo PrandoniH-Index: 87
#2Walter Ageno (University of Insubria)H-Index: 45
Last.Franco Noventa (UNIPD: University of Padua)H-Index: 44
view all 10 authors...
The novel direct oral anticoagulants (DOAC) have been shown to be at least as effective as and safer than conventional anticoagulants for the initial and long-term treatment of venous thromboembolic disorders. However, the rate of post-thrombotic syndrome (PTS) in patients with deep-vein thrombosis (DVT) treated with the DOACs is unknown. With the adoption of the Villalta scale, we assessed the rate of PTS at the end of the follow-up period in a consecutive series of 309 outpatients with acute p...
1 CitationsSource
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Noémie Kraaijpoel (UvA: University of Amsterdam)H-Index: 6
Last.Nick van Es (UvA: University of Amsterdam)H-Index: 17
view all 11 authors...
Abstract Background The Ottawa score was previously developed to predict recurrent venous thromboembolism (VTE) in cancer patients with VTE. The performance of this score in patients with incidental VTE is currently unclear. Aim To evaluate the performance of the Ottawa risk score in cancer patients with incidental pulmonary embolism included in an international, prospective, observational cohort study. Methods The score was used to classify patients as high (≥1), intermediate (0), or low risk (...
#1Marcello Di NisioH-Index: 30
#2Nick van EsH-Index: 17
Last.Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 9 authors...
Background: Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the initial 6 months is suggested in this patient population, but evidence supporting this approach is limited. Methods: The Hokusai VTE Cancer trial compared edoxaban with dalteparin for VTE treatment in patients with active cancer. This post hoc analysis focused on the follow-up period from 6 to 12 months. The primary outcome was the composi...
#1Noémie Kraaijpoel (UvA: University of Amsterdam)H-Index: 6
#2S.M. Bleker (UvA: University of Amsterdam)H-Index: 4
Last.Marcello Di NisioH-Index: 30
view all 21 authors...
PURPOSEPulmonary embolism is incidentally diagnosed in up to 5% of patients with cancer on routine imaging scans. The clinical relevance and optimal therapy for incidental pulmonary embolism, parti...
3 CitationsSource
#1Marcello Di Nisio (UvA: University of Amsterdam)H-Index: 30
#2Nick van Es (UvA: University of Amsterdam)H-Index: 17
Last.Ettore PorrecaH-Index: 28
view all 14 authors...
The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, PROTECHT, CONKO, and ONKOTEV scores for the first 3-6 months and for 12 months, and re-assessed scores after 3-6 months to determine the influence of variations in patients' risk classification on performance. Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first or...